Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when NRIX files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsNurix lands $700M upfront in Roche deal for BTK degrader, up to $2.3B total at stake
Filed June 8, 2026 · Period ending June 6, 2026 · ~1 min read
Key Changes
-
high
Roche pays $700 million cash upfront to license bexobrutideg, Nurix's experimental brain-penetrant BTK degrader, with up to $1.6 billion more in milestone payments tied to development, regulatory approval, and sales performance.
Item 1.01: Material Agreement verify on EDGAR → -
high
Nurix must fund 40% of global development costs and build a U.S. sales force, raising concerns about whether the company has adequate resources—potentially requiring future capital raises despite the large upfront payment.
Item 1A: Risk Factors view on EDGAR → -
high
Companies will split U.S. profits equally; Nurix receives low-to-high teens royalties on ex-U.S. sales, retaining significant economics but also bearing substantial cost obligations across multiple clinical trials.
Item 1.01: Cost Sharing verify on EDGAR → -
medium
Deal requires antitrust clearance under HSR Act before becoming effective, introducing timing uncertainty for when Nurix receives the $700 million payment and collaboration activities can begin.
Item 1.01: Conditions verify on EDGAR →
Summary
Nurix Therapeutics struck a major partnership with pharmaceutical giant Roche to co-develop bexobrutideg, an investigational oral drug that degrades Bruton's tyrosine kinase and can penetrate the brain. Roche will pay $700 million upfront and Nurix can earn up to $1.6 billion more through development, regulatory, and sales milestones.
The companies will share U.S. profits equally while Roche handles international markets, paying Nurix royalties in the low-to-high teens. Retail investors should note this validates Nurix's science with a top-tier partner but comes with significant strings attached.
Nurix must fund 40% of global development costs across multiple trials and build its own U.S. sales organization—a major operational and financial undertaking. The company explicitly flagged concerns about having adequate resources, suggesting future dilution through equity raises remains likely despite the large upfront check. Watch for HSR antitrust clearance timing, which gates when Nurix actually receives the $700 million, and listen to management's June 8 conference call for details on cash runway and development timelines. The deal transforms Nurix from a solo clinical-stage company into a co-commercialization partner with substantial near-term obligations.
Section-by-Section Diff
Event · Item 1.01 — Entry into a Material Definitive Agreement
Nurix entered a $700M upfront collaboration with Roche to co-develop and commercialize bexobrutideg, with up to $2.3B in total potential payments.
Added in current filing · verify on EDGAR →
On June 6, 2026, Nurix Therapeutics, Inc. (“Nurix”) entered into a License and Collaboration Agreement (the “Collaboration Agreement”), dated as of June 8, 2026, with F. Hoffmann-La Roche Ltd. and Genentech, Inc. (collectively, “Roche”), pursuant to which Nurix will grant Roche an exclusive worldwide license, including with respect to Nurix and its affiliates, under certain Nurix intellectual property rights to develop, manufacture, commercialize and otherwise exploit bexobrutideg (NX-5948), Nurix’s investigational, oral, brain-penetrant small molecule degrader of Bruton’s tyrosine kinase (BTK), and products comprising or containing bexobrutideg (collectively, “bexobrutideg”), subject to limited licenses Roche will grant to Nurix to perform Nurix’s development, manufacturing, commercialization and other activities under the Collaboration Agreement.
Nurix granted Roche an exclusive worldwide license to develop, manufacture, and commercialize bexobrutideg, an investigational oral BTK degrader. The companies will co-develop and co-commercialize the drug in the United States, while Roche handles development and commercialization outside the U.S.
Added in current filing · verify on EDGAR →
Under the Collaboration Agreement, Roche will make an upfront cash payment of $700.0 million to Nurix, and Nurix will be eligible to receive development, regulatory, and sales milestone payments, with total potential payments of up to $2.3 billion, including the upfront payment.
Roche will pay Nurix $700 million upfront in cash. Nurix can earn additional development, regulatory, and sales milestone payments bringing total potential payments to $2.3 billion. This represents significant near-term cash and substantial long-term revenue opportunity tied to bexobrutideg's development and commercial success.
Added in current filing · verify on EDGAR →
Development costs under the global development plan will be shared 40% by Nurix and 60% by Roche, subject to specified exceptions. Nurix and Roche will equally share profits and losses from U.S. commercialization and Nurix will be eligible to receive tiered royalties at rates ranging from the low teens to the high teens on ex-U.S. sales.
Nurix will fund 40% of global development costs while Roche covers 60%. In the U.S., the companies will split profits and losses equally. Outside the U.S., Nurix will receive tiered royalties in the low-to-high teens percentage range on sales, meaning Nurix retains significant economics but also bears substantial development cost obligations.
Added in current filing · verify on EDGAR →
The Collaboration Agreement will become effective upon the expiration or termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the “HSR Act”), and the expiration, termination or resolution of all other required waiting periods, clearance decisions or outstanding inquiries under antitrust laws.
The agreement is not yet effective and is contingent on antitrust clearance under the HSR Act and other applicable antitrust laws. Until these regulatory waiting periods expire or are cleared, the $700 million upfront payment and other collaboration activities cannot commence, introducing timing uncertainty.
Added in current filing · verify on EDGAR →
whether Nurix will have adequate resources to fund its obligations under the Nurix-Roche collaboration, including increased operating expenses in connection with funding 40% of development costs across multiple clinical trials and 2 establishing and maintaining a commercialization organization in the United States
Nurix disclosed risk that it may lack adequate resources to fund its 40% share of development costs across multiple trials and to build a U.S. commercialization organization. This indicates the collaboration will significantly increase Nurix's cash burn and operational complexity, potentially requiring additional capital raises.
Event · Item 7.01 — Regulation FD Disclosure
Nurix announced a collaboration agreement with Roche and scheduled a conference call to discuss the partnership.
Added in current filing · verify on EDGAR →
On June 7, 2026, Nurix issued a press release announcing (i) Nurix’s entry into the Collaboration Agreement and (ii) that on June 8, 2026, at 8:00 a.m. Eastern Time, Nurix will host a conference call and webcast to discuss the collaboration between Nurix and Roche.
Nurix has entered into a collaboration agreement with Roche, a major pharmaceutical company. The company is hosting a conference call on June 8, 2026 to provide details about this partnership. The specific terms and scope of the collaboration are not disclosed in this 8-K filing itself, but will be discussed in the upcoming call.
Event · Item 9.01 — Financial Statements and Exhibits
Nurix filed exhibits including a press release dated June 7, 2026 and a presentation dated June 8, 2026.
Show 1 minor / wording change
Added in current filing · view on EDGAR →
99.1 Nurix Therapeutics, Inc. Press Release dated June 7, 2026 99.2 Nurix Therapeutics, Inc. Presentation dated June 8, 2026
The company filed two exhibits: a press release dated June 7, 2026 and a presentation dated June 8, 2026. The 8-K does not disclose the content of these materials, only that they were filed as exhibits.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 9, 2026 · How we verify